Results 131 to 140 of about 28,587 (260)
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT We report a case of severe post‐tuberculosis lung disease (PTLD) in a 60‐year‐old Ugandan man with a six‐year history of suboptimally treated pulmonary tuberculosis (PTB), who presented with a three‐week history of productive cough, yellow foul‐smelling sputum occasionally streaked with blood, dyspnea, pleuritic chest pain, fatigue and ...
Abdisalam Ahmed Sandeyl +6 more
wiley +1 more source
International Journal of COPDJong Geol Jang,* Young Seok Lee,* Kyung Soo Hong, June Hong Ahn Division of Pulmonology and Allergy, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Republic of Korea*These ...
Jang JG, Lee YS, Hong KS, Ahn JH
doaj
Indacaterol versus other long acting β2 agonist bronchodilators on FEV1 at 12 weeks.
, 2013 Indacaterol versus other long acting β2 agonist bronchodilators on FEV1 at 12 weeks.
Polly H. X. Ma (115746) +4 more
core +1 more source
The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 6, June 2026.ABSTRACT Pediatric asthma is a common chronic airway inflammatory disease, where accurate assessment of disease severity and prognosis prediction is crucial for treatment decisions. Currently, there is a lack of precise and effective biomarkers.
Xu Yang +5 more
wiley +1 more source
Pediatric Pulmonology, Volume 61, Issue 6, June 2026.ABSTRACT Background As a part of the Irish Comparative Outcome national cohort study of childhood CF, this cross‐sectional study investigated challenges faced by parents of children with CF (CWCF) in the Republic of Ireland using a newly validated modified tool. Methods Parents completed the modified “Challenge of Living with Cystic Fibrosis‐Short Form”
Rini Bhatnagar +22 more
wiley +1 more source
Respirology, Volume 31, Issue 6, Page 561-577, June 2026.ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley +1 more source
Allergy, Volume 81, Issue 6, Page 2172-2183, June 2026.Rapid clinical relief of allergy symptoms during 18 months of sublingual immunotherapy (SLIT) for house dust mite (HDM) is associated with increased serum IgE, IgG2, and IgG4 to Der p 1 and Der p 2. Der p 1 and Der p 2 specific Type 2 memory B cells are expanded at 4 months and 12 months of SLIT, with increased expression of CD29 and IgG4.
Lin Hsin +9 more
wiley +1 more source
Reducing cholinergic constriction: the major reversible mechanism in COPD
European Respiratory Review, 2006 The airway narrowing in chronic obstructive pulmonary disease (COPD) has often been misunderstood as being irreversible. However, a large proportion of patients with COPD do respond to bronchodilator agents with significant changes in lung function ...
V. Brusasco
doaj
Fentanyl Compromises Lower‐Airway Mechanics and Naloxone Triggers a Transient Mechanical Overshoot
Acta Physiologica, Volume 242, Issue 6, June 2026.ABSTRACT Aim Opioid‐induced respiratory depression (OIRD) is the leading cause of death following opioid overdose, due to its effects on central rhythm generation, and airway and thoracic constriction. While the effects on rhythm generation have been well documented, the effects of fentanyl on airway constriction are less well understood. We tested the
Riley R. Parks +4 more
wiley +1 more source
Prevention of exacerbations of COPD with pharmacotherapy
European Respiratory Review, 2010 Exacerbations are a frequent event in the evolution of chronic obstructive pulmonary disease (COPD) patients. Individuals with COPD have a mean of 1–3 episodes per year, some of which lead to hospital admission and may even be a cause of death.
M. Miravitlles
doaj